Abstract

BackgroundHand function deterioration is a major multifactorial driver of disability in Systemic Sclerosis (SSc) whose rate has been poorly described.ObjectivesThe aim of this study is to describe incidence and risk...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
POS0876 SERUM INTERFERON SCORE PREDICTS SEVERITY OF PATIENT REPORTED HAND DISABILITY IN SYSTEMIC SCLEROSIS
E De Lorenzis ... P Helliwell
-
E De Lorenzis, et. al.E De Lorenzis ... P Helliwell
23 May 2022
Minimal clinically important differences (MCID) and patient acceptable symptomatic state (PASS) for visual analog scales (VAS) measuring pain in patients treated for rotator cuff disease
Robert Z Tashjian ... Julia Deloach
Journal of shoulder and elbow surgery | VOL. 18
Robert Z Tashjian, et. al.Robert Z Tashjian ... Julia Deloach
16 Jun 2009
The Minimal Clinical Important Difference (MCID) And Patient Acceptable Symptomatic State (PASS) For The Modified Harris Hip Score And Hip Outcome Score Among Patients Undergoing Surgical Treatment For Femoroacetabular Impingement
Jaskarndip Chahal ... Michael Jonathan Salata
Orthopaedic journal of sports medicine | VOL. 2
Jaskarndip Chahal, et. al.Jaskarndip Chahal ... Michael Jonathan Salata
01 Jul 2014
Preoperative Disability Influences Effectiveness of MCID and PASS in Predicting Patient Improvement Following Lumbar Spine Surgery.
Pratyush Shahi ... Evan Sheha
Clinical spine surgery | VOL. 36
Pratyush Shahi, et. al.Pratyush Shahi ... Evan Sheha
29 Aug 2023
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Itaconate is a metabolic regulator of bone formation in homeostasis and arthritis
Markus Kieler ... Stephan Blüml
Annals of the Rheumatic Diseases | VOL. -
Markus Kieler, et. al.Markus Kieler ... Stephan Blüml
10 Jul 2024
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
Matthew A Brown ... Irene Van Der Horst-Bruinsma
Annals of the Rheumatic Diseases | VOL. -
Matthew A Brown, et. al.Matthew A Brown ... Irene Van Der Horst-Bruinsma
08 Jul 2024
Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease
Yusuke Yoshimura ... Naoki Sawa
Annals of the Rheumatic Diseases | VOL. -
Yusuke Yoshimura, et. al.Yusuke Yoshimura ... Naoki Sawa
04 Jul 2024
Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis
Katerina Kachler ... Aline Bozec
Annals of the Rheumatic Diseases | VOL. -
Katerina Kachler, et. al.Katerina Kachler ... Aline Bozec
04 Jul 2024
View more papers